Compared to the control group, SGLT2 inhibitors was associated with reduced risk of the secondary outcomes of hospitalization (HR 0.94 (0.90, 0.98), ARR 1.06 (1.36, 1.76)) anemia (HR 0.71 (0.65, 0.76), ARR 2.43 (1.95, 2.90)), and AKI (HR 0.84 (0.79, 0.89), ARR 1.86 (1.29, 2.42)) (Fig. 3, Supplementary Table 4). Here, SLC5A2 is linked to anemia (phenotype).